Photo of Prof Andrew Pettitt

Prof Andrew Pettitt MA, MB BChir, PhD, MRCP, FRCPath

Ronald Finn Professor of Experimental Medicine and Honorary Consultant Haematologist (Clatterbridge Cancer Centre) Molecular and Clinical Cancer Medicine

Publications

2019

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. (Journal article)

Kreuzer, K. -A., Furman, R. R., Stilgenbauer, S., Dubowy, R. L., Kim, Y., Munugalavadla, V., . . . Hallek, M. (2019). The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.. Leukemia. doi:10.1038/s41375-019-0533-6

DOI: 10.1038/s41375-019-0533-6

A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL (Journal article)

Eyre, T. A., Hildyard, C., Hamblin, A., Ali, A. S., Houlton, A., Hopkins, L., . . . Collins, G. P. (2019). A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. HEMATOLOGICAL ONCOLOGY, 37(4), 352-359. doi:10.1002/hon.2662

DOI: 10.1002/hon.2662

Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. (Journal article)

Wojdacz, T. K., Amarasinghe, H. E., Kadalayil, L., Beattie, A., Forster, J., Blakemore, S. J., . . . Strefford, J. C. (2019). Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. BLOOD ADVANCES, 3(16), 2474-2481. doi:10.1182/bloodadvances.2019000237

DOI: 10.1182/bloodadvances.2019000237

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study (Journal article)

Hillmen, P., Rawstron, A. C., Brock, K., Munoz-Vicente, S., Yates, F. J., Bishop, R., . . . Munir, T. (2019). Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. JOURNAL OF CLINICAL ONCOLOGY, 37(30), 2722-+. doi:10.1200/JCO.19.00894

DOI: 10.1200/JCO.19.00894

Potential therapeutic advantage for duvelisib in Mantle cell lymphoma: PI3Kδ and overexpressed PI3Kγ in lymphoma cells have specialized functional roles (Conference Paper)

Till, K. J., Janet, G. Z., Marks, T., Weaver, D., Pachter, J., Abdullah, M., . . . Slupsky, J. R. (2019). Potential therapeutic advantage for duvelisib in Mantle cell lymphoma: PI3Kδ and overexpressed PI3Kγ in lymphoma cells have specialized functional roles. In Hematological Oncology Vol. 37 (pp. 511-512). Lugano: Wiley-Blackwell.

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia (Journal article)

Sharman, J. P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . Stilgenbauer, S. (2019). Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 37(16), 1391-1402. doi:10.1200/JCO.18.01460

DOI: 10.1200/JCO.18.01460

Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ (Journal article)

Al-Jameel, W., Gou, X., Jin, X., Zhang, J., Wei, Q., Ai, J., . . . Ke, Y. (2019). Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ. Genes and Cancer, 10(3-4), 80-96. doi:10.18632/genesandcancer.192

DOI: 10.18632/genesandcancer.192

Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial. (Conference Paper)

Offner, F., Robak, T., Janssens, A., Kanakasetty, G. B., Kloczko, J., Grosicki, S., . . . Hillmen, P. (2019). Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. Retrieved from http://gateway.webofknowledge.com/

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma (Journal article)

Flinn, I. W., Miller, C. B., Ardeshna, K. M., Tetreault, S., Assouline, S. E., Mayer, J., . . . Zinzani, P. L. (2019). DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 37(11), 912-+. doi:10.1200/JCO.18.00915

DOI: 10.1200/JCO.18.00915

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study (Conference Paper)

Munir, T., Rawstron, A., Brock, K., Vicente, S. M., Yates, F., Bishop, R., . . . Hillmen, P. (2019). Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 185 (pp. 25). Retrieved from http://gateway.webofknowledge.com/

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with > 1 Year Prior Ibrutinib Exposure (Conference Paper)

Munir, T., Rawstron, A., Brock, K., Vicente, S. M., Yates, F., Bishop, R., . . . Hillmen, P. (2019). Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with > 1 Year Prior Ibrutinib Exposure. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 185 (pp. 85-86). Retrieved from http://gateway.webofknowledge.com/

2018

Highly Comprehensive Genomic Testing for CLL: WGS, One Key to CLL Patient Stratification (Conference Paper)

Ridout, K. E., Robbe, P., Cavalieri, D., Becq, J., He, M., Clifford, R., . . . Schuh, A. (2018). Highly Comprehensive Genomic Testing for CLL: WGS, One Key to CLL Patient Stratification. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-115935

DOI: 10.1182/blood-2018-99-115935

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study (Conference Paper)

Hillmen, P., Rawstron, A., Brock, K., Vicente, S. M., Yates, F., Bishop, R., . . . Munir, T. (2018). Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. In BLOOD Vol. 132. doi:10.1182/blood-2018-182

DOI: 10.1182/blood-2018-182

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with > 1 Year Prior Ibrutinib Exposure (Conference Paper)

Rawstron, A., Munir, T., Brock, K., Webster, N., Vicente, S. M., Yates, F., . . . Hillmen, P. (2018). Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with > 1 Year Prior Ibrutinib Exposure. In BLOOD Vol. 132. doi:10.1182/blood-2018-181

DOI: 10.1182/blood-2018-181

Population Based Observational Study Demonstrates Significant Increase in Watch-and-Wait for Newly Diagnosed Mantle Cell Lymphoma (Conference Paper)

McCulloch, R., Berrow, M., Wainman, B., Crosbie, N., Pettitt, A., & Rule, S. (2018). Population Based Observational Study Demonstrates Significant Increase in Watch-and-Wait for Newly Diagnosed Mantle Cell Lymphoma. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-114528

DOI: 10.1182/blood-2018-99-114528

Central nervous system plasmablastic lymphoma evolving from polyclonal plasmacytosis (Journal article)

Khan, U. T., Racu-Amoasii, I., Arumainathan, A., Meswani, U., Pettitt, A. R., & Menon, G. (2018). Central nervous system plasmablastic lymphoma evolving from polyclonal plasmacytosis. BRITISH JOURNAL OF HAEMATOLOGY, 183(3), 345. doi:10.1111/bjh.15489

DOI: 10.1111/bjh.15489

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma (Journal article)

Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., . . . Stankovic, T. (2018). A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 182(3), 429-433. doi:10.1111/bjh.14793

DOI: 10.1111/bjh.14793

Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline (Journal article)

Schuh, A. H., Parry-Jones, N., Appleby, N., Bloor, A., Dearden, C. E., Fegan, C., . . . Hillmen, P. (2018). Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline. BRITISH JOURNAL OF HAEMATOLOGY, 182(3), 344-359. doi:10.1111/bjh.15460

DOI: 10.1111/bjh.15460

The clinical importance of DNA methylation signatures in chronic lymphocytic leukemia patients treated with chemo-immunotherapy (Conference Paper)

Wojdacz, T. K., Amarasinghe, H. E., Rose-Zerilli, M. J. J., Beattie, A., Forster, J., Kadalayil, L., . . . Strefford, J. C. (2018). The clinical importance of DNA methylation signatures in chronic lymphocytic leukemia patients treated with chemo-immunotherapy. In CANCER RESEARCH Vol. 78. doi:10.1158/1538-7445.AM2018-3306

DOI: 10.1158/1538-7445.AM2018-3306

An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects. (Journal article)

Alharthi, A., Beck, D., Howard, D. R., Hillmen, P., Oates, M., Pettitt, A., & Wagner, S. D. (2018). An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects.. BMC research notes, 11(1), 280. doi:10.1186/s13104-018-3391-9

DOI: 10.1186/s13104-018-3391-9

Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy (Conference Paper)

Munir, T., Rawstron, A., Brock, K., Vicente, S. M., Yates, F., Bishop, R., . . . Hillmen, P. (2018). Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 34-35). Retrieved from http://gateway.webofknowledge.com/

Patients with a Memory-like DNA Methylation Signature exhibit long-term survival after first-line immuno-chemotherapy: Data from the UK CLL4, ARCTIC and ADMIRE trials (Conference Paper)

Amarasinghe, H., Wojdacz, T., Rose-Zerilli, M., Beattie, A., Forster, J., Kadalayil, L., . . . Strefford, J. (2018). Patients with a Memory-like DNA Methylation Signature exhibit long-term survival after first-line immuno-chemotherapy: Data from the UK CLL4, ARCTIC and ADMIRE trials. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 29). Retrieved from http://gateway.webofknowledge.com/

Whole genome sequencing in the clinic identifies CLL patients with high risk of relapse: pilot study for the 100,000 Genomes Project (Conference Paper)

Robbe, P., Ridout, K., Becq, J., He, M., Clifford, R., Burns, A., . . . Schuh, A. (2018). Whole genome sequencing in the clinic identifies CLL patients with high risk of relapse: pilot study for the 100,000 Genomes Project. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 28). Retrieved from http://gateway.webofknowledge.com/

2017

A phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma (Conference Paper)

Stankovic, T., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., . . . Devereux, S. (2017). A phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 110-111). Retrieved from http://gateway.webofknowledge.com/

Addition of obinutuzumab to ibrutinib enhances depletion of CLL cells in the peripheral blood and bone marrow after 1 month & 6 months of combination therapy: initial results from the bloodwise TAP IcICLLe extension study (Conference Paper)

Rawstron, A., Munir, T., Munoz-Vicente, S., Brock, K., Yates, F., Bishop, R., . . . Hillmen, P. (2017). Addition of obinutuzumab to ibrutinib enhances depletion of CLL cells in the peripheral blood and bone marrow after 1 month & 6 months of combination therapy: initial results from the bloodwise TAP IcICLLe extension study. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 233-234). Retrieved from http://gateway.webofknowledge.com/

Improved overall survival of relapsed chronic lymphocytic leukemia (CLL) patients exhibiting a complex karyotype and treated with idelalisib plus rituximab (Conference Paper)

Kreuzer, K. -A., Furman, R., Stilgenbauer, S., Dubowy, R., Kim, Y., Munugalavadla, V., . . . Hallek, M. (2017). Improved overall survival of relapsed chronic lymphocytic leukemia (CLL) patients exhibiting a complex karyotype and treated with idelalisib plus rituximab. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 167-168). Retrieved from http://gateway.webofknowledge.com/

Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome (Journal article)

Till, K. J., Allen, J. C., Talab, F., Lin, K., Allsup, D., Cawkwell, L., . . . Slupsky, J. R. (2017). Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. SCIENTIFIC REPORTS, 7. doi:10.1038/s41598-017-17021-w

DOI: 10.1038/s41598-017-17021-w

Linking genotype to clinical phenotype through proteomic analysis of CLL trial samples (Conference Paper)

Eagle, G., Zhuang, J., Oates, M., Kitteringham, N., Herbert, J., Falciani, F., . . . Hillmen, P. (2017). Linking genotype to clinical phenotype through proteomic analysis of CLL trial samples. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 100-101). Retrieved from http://gateway.webofknowledge.com/

Use of differentiated THP. 1 cells to mimic nurse-like cells for its pro-survival effect on chronic lymphocytic leukaemia cells (Conference Paper)

Mohammad, I. S., Zhuang, J., Pettitt, A., Oates, M., & Lin, K. (2017). Use of differentiated THP. 1 cells to mimic nurse-like cells for its pro-survival effect on chronic lymphocytic leukaemia cells. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 102-104). Retrieved from http://gateway.webofknowledge.com/

LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia (Journal article)

Gohil, S. H., Maciocia, N., Patrick, P., Roberts, T., Counsell, N., Smith, P., . . . Nathwani, A. C. (2018). LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA, 59(7), 1730-1733. doi:10.1080/10428194.2017.1399311

DOI: 10.1080/10428194.2017.1399311

Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia (Journal article)

Chapman, E. A., Oates, M., Mohammad, I. S., Davies, B. R., Stockman, P. K., Zhuang, J., & Pettitt, A. R. (2017). Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia. ONCOTARGET, 8(61), 102948-102964. doi:10.18632/oncotarget.22292

DOI: 10.18632/oncotarget.22292

Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL (Journal article)

Munir, T., Howard, D. R., McParland, L., Pocock, C., Rawstron, A. C., Hockaday, A., . . . Hillmen, P. (2017). Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. LEUKEMIA, 31(10), 2085-2093. doi:10.1038/leu.2017.65

DOI: 10.1038/leu.2017.65

A IBRUTINIB RESULTS IN REDUCTION OF PHOSPHORYLATION OF MULTIPLE KINASES IN THE B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE BLOODWISE TAP ICICLLE STUDY (Conference Paper)

Munir, T., Rawstron, A., Munoz-Vicente, S., Brock, K., Yates, F., Bishop, R., . . . Hillmen, P. (2017). A IBRUTINIB RESULTS IN REDUCTION OF PHOSPHORYLATION OF MULTIPLE KINASES IN THE B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE BLOODWISE TAP ICICLLE STUDY. In HAEMATOLOGICA Vol. 102 (pp. 229-230). Retrieved from http://gateway.webofknowledge.com/

ADDING OBINUTUZUMAB TO IBRUTINIB ENHANCES DEPLETION OF CLL CELLS IN PERIPHERAL BLOOD AND BONE MARROW AFTER 1 & 6 MONTHS COMBINED THERAPY INITIAL RESULTS FROM THE BLOODWISE TAP ICICLLE EXTENSION STUDY (Conference Paper)

Rawstron, A., Munir, T., Munoz-Vicente, S., Brock, K., Yates, F., Bishop, R., . . . Hillmen, P. (2017). ADDING OBINUTUZUMAB TO IBRUTINIB ENHANCES DEPLETION OF CLL CELLS IN PERIPHERAL BLOOD AND BONE MARROW AFTER 1 & 6 MONTHS COMBINED THERAPY INITIAL RESULTS FROM THE BLOODWISE TAP ICICLLE EXTENSION STUDY. In HAEMATOLOGICA Vol. 102 (pp. 69). Retrieved from http://gateway.webofknowledge.com/

DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY FOLLICULAR LYMPHOMA (Conference Paper)

Zinzani, P. L., Wagner-Johnston, N., Miller, C., Ardeshna, K., Tertreault, S., Assouline, S., . . . Flinn, I. (2017). DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY FOLLICULAR LYMPHOMA. In HAEMATOLOGICA Vol. 102 (pp. 315). Retrieved from http://gateway.webofknowledge.com/

Optimising Technical Protocols to Detect AID Expression in Archived FFPE Samples of Patients with Follicular Lymphoma (Conference Paper)

Alishlash, O., Lin, K., Coupland, S., Oates, M., Kalirai, H., & Pettitt, A. (2017). Optimising Technical Protocols to Detect AID Expression in Archived FFPE Samples of Patients with Follicular Lymphoma. In JOURNAL OF PATHOLOGY Vol. 241 (pp. S11). Retrieved from http://gateway.webofknowledge.com/

Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia (Journal article)

Law, P. J., Berndt, S. I., Speedy, H. E., Camp, N. J., Sava, G. P., Skibola, C. F., . . . Slager, S. L. (2017). Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. NATURE COMMUNICATIONS, 8. doi:10.1038/ncomms14175

DOI: 10.1038/ncomms14175

Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci (Journal article)

Law, P. J., Sud, A., Mitchell, J. S., Henrion, M., Orlando, G., Lenive, O., . . . Houlston, R. S. (2017). Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. SCIENTIFIC REPORTS, 7. doi:10.1038/srep41071

DOI: 10.1038/srep41071

2016

Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study (Conference Paper)

Rawstron, A. C., Munir, T., Munoz-Vicente, S., Brock, K., Yates, F. J., Bishop, R., . . . Hillmen, P. (2016). Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.2049.2049

DOI: 10.1182/blood.V128.22.2049.2049

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma (Conference Paper)

Flinn, I. W., Miller, C. B., Ardeshna, K. M., Tetreault, S., Assouline, S. E., Zinzani, P. L., . . . Wagner-Johnston, N. D. (2016). Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.1218.1218

DOI: 10.1182/blood.V128.22.1218.1218

Identifying High-Risk CLL to Predict Early Relapse after FCR Based Treatment Using Whole Genome Sequencing: First Results from the Genomics England CLL Pilot (Conference Paper)

Robbe, P., Ridout, K., Becq, J., He, M., Clifford, R., Alsolami, R., . . . Schuh, A. (2016). Identifying High-Risk CLL to Predict Early Relapse after FCR Based Treatment Using Whole Genome Sequencing: First Results from the Genomics England CLL Pilot. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.2022.2022

DOI: 10.1182/blood.V128.22.2022.2022

Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia (Conference Paper)

Kreuzer, K. -A., Furman, R. R., Stilgenbauer, S., Dubowy, R. L., Kim, Y., Munugalavadla, V., . . . Hallek, M. (2016). Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.192.192

DOI: 10.1182/blood.V128.22.192.192

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia (Journal article)

Parker, H., Rose-Zerilli, M. J. J., Larrayoz, M., Clifford, R., Edelmann, J., Blakemore, S., . . . Strefford, J. C. (2016). Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. LEUKEMIA, 30(11), 2179-2186. doi:10.1038/leu.2016.134

DOI: 10.1038/leu.2016.134

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome (Journal article)

Eyre, T. A., Clifford, R., Bloor, A., Boyle, L., Roberts, C., Cabes, M., . . . Schuh, A. (2016). NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. BRITISH JOURNAL OF HAEMATOLOGY, 175(1), 43-54. doi:10.1111/bjh.14177

DOI: 10.1111/bjh.14177

Longitudinal bioimpedance assessments to evaluate hydration in POEMS syndrome (Journal article)

Nwosu, A. C., Morris, L., Mayland, C., Mason, S., Pettitt, A., & Ellershaw, J. (2016). Longitudinal bioimpedance assessments to evaluate hydration in POEMS syndrome. BMJ SUPPORTIVE & PALLIATIVE CARE, 6(3), 369-372. doi:10.1136/bmjspcare-2015-000991

DOI: 10.1136/bmjspcare-2015-000991

DISCONTINUATION OF IDELALISIB TREATMENT DUE TO DISEASE PROGRESSION IN PATIENTS WITH RELAPSED AND REFRACTORY CLL: AN EVALUATION OF OUTCOMES (Conference Paper)

Brown, J. R., Ghia, P., Jones, J. A., Pettitt, A. R., Sharman, J. P., Ysebaert, L., . . . Stilgenbauer, S. (2016). DISCONTINUATION OF IDELALISIB TREATMENT DUE TO DISEASE PROGRESSION IN PATIENTS WITH RELAPSED AND REFRACTORY CLL: AN EVALUATION OF OUTCOMES. In HAEMATOLOGICA Vol. 101 (pp. 54). Retrieved from http://gateway.webofknowledge.com/

FINAL RESULTS OF THE NCRI CLL210 TRIAL OF ALEMTUZUMAB, DEXAMETHASONE AND LENALIDOMIDE IN PATIENTS WITH HIGH-RISK CLL (ORIGINAL PROTOCOL) (Conference Paper)

Pettitt, A. R., Polydoros, F., Dodd, J., Oates, M., Lin, K., Kalakonda, N., . . . Hillmen, P. (2016). FINAL RESULTS OF THE NCRI CLL210 TRIAL OF ALEMTUZUMAB, DEXAMETHASONE AND LENALIDOMIDE IN PATIENTS WITH HIGH-RISK CLL (ORIGINAL PROTOCOL). In HAEMATOLOGICA Vol. 101 (pp. 726). Retrieved from http://gateway.webofknowledge.com/

LINKING PROTEOME AND GENOME FOR BIOMARKER DISCOVERY IN CLL-ESTABLISHMENT OF A CLL PROTEIN DATABASE (Conference Paper)

Eagle, G. L., Zhuang, J., Jenkins, R., Kitteringham, N., Oates, M., Park, K., . . . Pettitt, A. (2016). LINKING PROTEOME AND GENOME FOR BIOMARKER DISCOVERY IN CLL-ESTABLISHMENT OF A CLL PROTEIN DATABASE. In HAEMATOLOGICA Vol. 101 (pp. 420-421). Retrieved from http://gateway.webofknowledge.com/

Outcomes of patients with relapsed and refractory chronic lynnphocytic leukemia (CLL) who discontinue idelalisib treatment. (Conference Paper)

Brown, J. R., Ghia, P., Jones, J. A., Pettitt, A., Sharman, J. P., Ysebaert, L., . . . Furman, R. R. (2016). Outcomes of patients with relapsed and refractory chronic lynnphocytic leukemia (CLL) who discontinue idelalisib treatment.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.7531

DOI: 10.1200/JCO.2016.34.15_suppl.7531

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study (Journal article)

Rawstron, A. C., Fazi, C., Agathangelidis, A., Villamor, N., Letestu, R., Nomdedeu, J., . . . CLL, E. E. R. I. (2016). A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. LEUKEMIA, 30(4), 929-936. doi:10.1038/leu.2015.313

DOI: 10.1038/leu.2015.313

Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus (vol 10, e0142379, 2015) (Journal article)

Hargreaves, C. E., Iriyama, C., Rose-Zerilli, M. J. J., Nagelkerke, S. Q., Hussain, K., Ganderton, R., . . . Strefford, J. C. (2016). Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus (vol 10, e0142379, 2015). PLOS ONE, 11(3). doi:10.1371/journal.pone.0145040

DOI: 10.1371/journal.pone.0145040

BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells (Journal article)

Butterworth, M., Pettitt, A., Varadarajan, S., & Cohen, G. M. (2016). BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells. BRITISH JOURNAL OF CANCER, 114(6), 638-641. doi:10.1038/bjc.2016.49

DOI: 10.1038/bjc.2016.49

2015

Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia (Conference Paper)

Rose-Zerilli, M. J. J., Parker, H., Larrayoz, M., Clifford, R., Blakemore, S., Edelmann, J., . . . Strefford, J. C. (2015). Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia. In BLOOD Vol. 126. Retrieved from http://gateway.webofknowledge.com/

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL (Journal article)

Guieze, R., Robbe, P., Clifford, R., de Guibert, S., Pereira, B., Timbs, A., . . . Schuh, A. (2015). Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. BLOOD, 126(18), 2110-2117. doi:10.1182/blood-2015-05-647578

DOI: 10.1182/blood-2015-05-647578

Distinct requirement of AKT for CD40-induced cell growth and division in chronic lymphocytic leukemia (Journal article)

Zhuang, J., Chapman, E., Stockman, P., Davies, B., & Pettitt, A. (2015). Distinct requirement of AKT for CD40-induced cell growth and division in chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA, 56, 16-18. Retrieved from http://gateway.webofknowledge.com/

Physical examination and MRD assessment rather than CT-scans is effective to assess responses in patients treated with fludarabine-based chemoimmunotherapy. Analysis of patients in the UK NCRI ADMIRE and ARCTIC trials (Journal article)

Munir, T., Cohen, D., Pocock, C., Rawstron, A., Collet, L., McParland, L., . . . Hillmen, P. (2015). Physical examination and MRD assessment rather than CT-scans is effective to assess responses in patients treated with fludarabine-based chemoimmunotherapy. Analysis of patients in the UK NCRI ADMIRE and ARCTIC trials. LEUKEMIA & LYMPHOMA, 56, 26-27. Retrieved from http://gateway.webofknowledge.com/

A LONGITUDINAL STUDY OF NEXT GENERATION SEQUENCING IN CHRONIC LYMPHOCYTIC LEUKEMIA SHOWS EVIDENCE OF CHEMOTHERAPY-INDUCED MUTAGENESIS AND SNOWBALLING EFFECT DUE TO LOSS OF P53/ATM-MEDIATED DNA REPAIR (Conference Paper)

Karim, S., Johnson, G., Pettitt, A., & Lin, K. (2015). A LONGITUDINAL STUDY OF NEXT GENERATION SEQUENCING IN CHRONIC LYMPHOCYTIC LEUKEMIA SHOWS EVIDENCE OF CHEMOTHERAPY-INDUCED MUTAGENESIS AND SNOWBALLING EFFECT DUE TO LOSS OF P53/ATM-MEDIATED DNA REPAIR. In HAEMATOLOGICA Vol. 100 (pp. 222-223). Retrieved from http://gateway.webofknowledge.com/

OPTIMISATION OF RNA EXTRACTION AND RT-QPCR FOR THE QUANTIFICATION OF AID IN ARCHIVED FFPE BIOPSY SAMPLES: ONLY TWO SECTIONS OF 4 MM TISSUE ARE REQUIRED (Conference Paper)

Alishlash, O., Pettitt, A., Coupland, S., & Lin, K. (2015). OPTIMISATION OF RNA EXTRACTION AND RT-QPCR FOR THE QUANTIFICATION OF AID IN ARCHIVED FFPE BIOPSY SAMPLES: ONLY TWO SECTIONS OF 4 MM TISSUE ARE REQUIRED. In HAEMATOLOGICA Vol. 100 (pp. 765). Retrieved from http://gateway.webofknowledge.com/

SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE FOR PATIENTS WITH NEWLY DIAGNOSED RICHTER'S SYNDROME (Conference Paper)

Eyre, T., Clifford, R., Bloor, A., Boyle, L., Cabes, M., Collins, G., . . . Schuh, A. (2015). SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE FOR PATIENTS WITH NEWLY DIAGNOSED RICHTER'S SYNDROME. In HAEMATOLOGICA Vol. 100 (pp. 109). Retrieved from http://gateway.webofknowledge.com/

Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia (Journal article)

Pagel, J. M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Hillmen, P., . . . Hallek, M. J. (2015). Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 15, S201-S202. doi:10.1016/j.clml.2015.04.062

DOI: 10.1016/j.clml.2015.04.062

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial (Journal article)

Hillmen, P., Robak, T., Janssens, A., Babu, K. G., Kloczko, J., Grosicki, S., . . . Investigators, C. O. M. P. L. E. M. E. N. T. 1. S. (2015). Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. LANCET, 385(9980), 1873-1883. doi:10.1016/S0140-6736(15)60027-7

DOI: 10.1016/S0140-6736(15)60027-7

Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results (Conference Paper)

Munir, T., Hillmen, P., Eradat, H., Ghia, P., O'Brien, S., Furman, R., . . . Wagner, L. (2015). Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 169 (pp. 53). Retrieved from http://gateway.webofknowledge.com/

Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. (Journal article)

Middle, S., Coupland, S. E., Taktak, A., Kidgell, V., Slupsky, J. R., Pettitt, A. R., & Till, K. J. (2015). Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins.. Experimental hematology & oncology, 4, 10. doi:10.1186/s40164-015-0004-3

DOI: 10.1186/s40164-015-0004-3

Next-generation sequencing in chronic lymphocytic leukaemia using Ion Torrent PGM shows evidence of chemotherapy-induced mutagenesis and a snowballing effect due to loss of p53/ATM-mediated DNA repair (Conference Paper)

Karim, S., Johnson, G., Pettitt, A., & Lin, K. (2015). Next-generation sequencing in chronic lymphocytic leukaemia using Ion Torrent PGM shows evidence of chemotherapy-induced mutagenesis and a snowballing effect due to loss of p53/ATM-mediated DNA repair. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 169 (pp. 73). Retrieved from http://gateway.webofknowledge.com/

Optimisation of RNA extraction and RT-qPCR for the quantification of AID in archived FFPE biopsy samples: only two sections of 4 mu m tissue are required (Conference Paper)

Alishlash, O., Coupland, S., Pettitt, A., & Lin, K. (2015). Optimisation of RNA extraction and RT-qPCR for the quantification of AID in archived FFPE biopsy samples: only two sections of 4 mu m tissue are required. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 169 (pp. 74-75). Retrieved from http://gateway.webofknowledge.com/

Total Proteome Analysis Identifies Migration Defects as a Major Pathogenetic Factor in Immunoglobulin Heavy Chain Variable Region (IGHV)-unmutated Chronic Lymphocytic Leukemia (Journal article)

Eagle, G., Zhuang, J., Jenkins, R., Till, K., Jithesh, P., Lin, K., . . . Pettitt, A. (2015). Total Proteome Analysis Identifies Migration Defects as a Major Pathogenetic Factor in Immunoglobulin Heavy Chain Variable Region (IGHV)-unmutated Chronic Lymphocytic Leukemia. Molecular and Cellular Proteomics, 14(4), 933-945. doi:10.1074/mcp.M114.044479

DOI: 10.1074/mcp.M114.044479

Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk (Journal article)

Sava, G. P., Speedy, H. E., Di Bernardo, M. C., Dyer, M. J. S., Holroyd, A., Sunter, N. J., . . . Houlston, R. S. (2015). Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. LEUKEMIA, 29(3), 748-751. doi:10.1038/leu.2014.311

DOI: 10.1038/leu.2014.311

Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase delta but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells (Journal article)

Till, K. J., Pettitt, A. R., & Slupsky, J. R. (2015). Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase delta but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells. JOURNAL OF IMMUNOLOGY, 194(5), 2439-2446. doi:10.4049/jimmunol.1402304

DOI: 10.4049/jimmunol.1402304

Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus (Journal article)

Hargreaves, C. E., Iriyama, C., Rose-Zerilli, M. J. J., Nagelkerke, S. Q., Hussain, K., Ganderton, R., . . . Strefford, J. C. (2015). Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus. PLOS ONE, 10(11). doi:10.1371/journal.pone.0142379

DOI: 10.1371/journal.pone.0142379

2014

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study (Journal article)

Rawstron, A., Fazi, C., Villamor, N., Delgado, J., Letestu, R., Cymbalista, F., . . . Ghia, P. (2014). A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. BLOOD, 124(21). Retrieved from http://gateway.webofknowledge.com/

Genomic Dissection of the Fc gamma Receptor Region in the Context of Monoclonal Antibody Therapy (Journal article)

Hargreaves, C., Iriyama, C., Rose-Zerilli, M. J. J., Lee, C., Potter, K., Ganderton, R., . . . Strefford, J. C. (2014). Genomic Dissection of the Fc gamma Receptor Region in the Context of Monoclonal Antibody Therapy. BLOOD, 124(21). Retrieved from http://gateway.webofknowledge.com/

Mutational Landscape of 118 Relapsed Chronic Lymphocytic Leukemia Clinical Trial Samples; Evidence for a Multiple-Hit Profile Using Targeted Next Generation Sequencing (Conference Paper)

Robbe, P., Guieze, R., Clifford, R. M., de Guibert, S., Timbs, A., Dilhuydy, M. -S., . . . Tournilhac, O. (2014). Mutational Landscape of 118 Relapsed Chronic Lymphocytic Leukemia Clinical Trial Samples; Evidence for a Multiple-Hit Profile Using Targeted Next Generation Sequencing. In BLOOD Vol. 124. Retrieved from http://gateway.webofknowledge.com/

The Identification of Further Minimal Regions of Overlap in Chronic Lymphocytic Leukemia Using High-Resolution SNP Arrays (Journal article)

Knight, S. J. L., Clifford, R., Robbe, P., Ramos, S. D. C., Burns, A., Timbs, A. T., . . . Shuh, A. (2014). The Identification of Further Minimal Regions of Overlap in Chronic Lymphocytic Leukemia Using High-Resolution SNP Arrays. BLOOD, 124(21). Retrieved from http://gateway.webofknowledge.com/

Total Proteome Analysis Identifies Migration Defects As a Major Pathogenetic Factor in IGHV-Unmutated Chronic Lymphocytic Leukemia (Conference Paper)

Eagle, G. L., Jenkins, R. E., Till, K. J., Puthen, J., Lin, K., Johnson, G. G., . . . Pettitt, A. R. (2014). Total Proteome Analysis Identifies Migration Defects As a Major Pathogenetic Factor in IGHV-Unmutated Chronic Lymphocytic Leukemia. In BLOOD Vol. 124. Retrieved from http://gateway.webofknowledge.com/

Towards Response Prediction Using Integrated Genomics in Chronic Lymphocytic Leukaemia: Results on 250 First-Line FCR Treated Patients from UK Clinical Trials (Conference Paper)

Clifford, R. M., Robbe, P., Weller, S., Timbs, A. T., Titsias, M., Burns, A., . . . Schuh, A. (2014). Towards Response Prediction Using Integrated Genomics in Chronic Lymphocytic Leukaemia: Results on 250 First-Line FCR Treated Patients from UK Clinical Trials. In BLOOD Vol. 124. Retrieved from http://gateway.webofknowledge.com/

Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia (Journal article)

Lin, K., Farahani, M., Yang, Y., Johnson, G. G., Oates, M., Atherton, M., . . . Pettitt, A. R. (2014). Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 167(3), 346-355. doi:10.1111/bjh.13043

DOI: 10.1111/bjh.13043

2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia (Journal article)

Hallek, M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., . . . Kroenig, H. (2014). 2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia. ONCOLOGY RESEARCH AND TREATMENT, 37, 183. Retrieved from http://gateway.webofknowledge.com/

Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL (Journal article)

Hallek, M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., . . . Schuster, A. (2014). Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL. ONCOLOGY RESEARCH AND TREATMENT, 37, 52-53. Retrieved from http://gateway.webofknowledge.com/

COMPARISON OF GEMCITABINE VS. NON-GEMCITABINE BASED SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE LYMPHOMA (Conference Paper)

Taylor, D., Angelillo, P., Ward, C., Collins, D., Salim, R., Pettitt, A., . . . Kalakonda, N. (2014). COMPARISON OF GEMCITABINE VS. NON-GEMCITABINE BASED SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE LYMPHOMA. In HAEMATOLOGICA Vol. 99 (pp. 701). Retrieved from http://gateway.webofknowledge.com/

HEALTH-RELATED QUALITY OF LIFE IMPACT OF IDELALISIB (IDELA) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PHASE 3 RESULTS (Conference Paper)

Eradat, H. A., Ghia, P., O'Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., . . . Wagner, L. I. (2014). HEALTH-RELATED QUALITY OF LIFE IMPACT OF IDELALISIB (IDELA) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PHASE 3 RESULTS. In HAEMATOLOGICA Vol. 99 (pp. 63). Retrieved from http://gateway.webofknowledge.com/

ORAL FCR INDUCES HIGHER COMPLETE REMISSION RATES AND MRD NEGATIVITY IN UNTREATED CLL THAN PREVIOUS REPORTS OF INTRAVENOUS THERAPY: COMBINED RESULTS OF THE NCRI ADMIRE AND ARCTIC TRIALS (Conference Paper)

Munir, T., Cohen, D., Pocock, C., Rawstron, A., McParland, L., Chalmers, A., . . . Hillmen, P. (2014). ORAL FCR INDUCES HIGHER COMPLETE REMISSION RATES AND MRD NEGATIVITY IN UNTREATED CLL THAN PREVIOUS REPORTS OF INTRAVENOUS THERAPY: COMBINED RESULTS OF THE NCRI ADMIRE AND ARCTIC TRIALS. In HAEMATOLOGICA Vol. 99 (pp. 54). Retrieved from http://gateway.webofknowledge.com/

PRE-TREATMENT WITH IDELALISIB MARKEDLY REDUCES RITUXIMAB INFUSION-RELATED REACTIONS AND INFUSION INTERRUPTIONS IN PATIENTS WITH CLL (Conference Paper)

Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., Barrientos, J. C., . . . Cheson, B. D. (2014). PRE-TREATMENT WITH IDELALISIB MARKEDLY REDUCES RITUXIMAB INFUSION-RELATED REACTIONS AND INFUSION INTERRUPTIONS IN PATIENTS WITH CLL. In HAEMATOLOGICA Vol. 99 (pp. 55). Retrieved from http://gateway.webofknowledge.com/

SECOND INTERIM ANALYSIS OF A PHASE 3 STUDY EVALUATING IDELALISIB AND RITUXIMAB FOR RELAPSED CLL (Conference Paper)

Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . Hallek, M. J. (2014). SECOND INTERIM ANALYSIS OF A PHASE 3 STUDY EVALUATING IDELALISIB AND RITUXIMAB FOR RELAPSED CLL. In HAEMATOLOGICA Vol. 99 (pp. 249-250). Retrieved from http://gateway.webofknowledge.com/

Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results. (Conference Paper)

Ghia, P., O'Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., . . . Wagner, L. I. (2014). Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.7099

DOI: 10.1200/jco.2014.32.15_suppl.7099

Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL. (Conference Paper)

Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . Hallek, M. J. (2014). Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.7012

DOI: 10.1200/jco.2014.32.15_suppl.7012

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukaemia (CLL) (NCRN375) (Conference Paper)

Hillmen, P., Furman, R., Sharmann, J., Coutre, S., Cheson, B., Pagel, J., . . . O'Brien, S. (2014). A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukaemia (CLL) (NCRN375). In BRITISH JOURNAL OF HAEMATOLOGY Vol. 165 (pp. 3). Retrieved from http://gateway.webofknowledge.com/

Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted) (Conference Paper)

Hillmen, P., Pettitt, A., Schuh, A., Milligan, D., Bowles, K., Bareford, D., . . . McKeown, A. (2014). Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted). In BRITISH JOURNAL OF HAEMATOLOGY Vol. 165 (pp. 19-20). Retrieved from http://gateway.webofknowledge.com/

Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold? (Journal article)

Johnson, G. G., Carr, D. F., Pirmohamed, M., & Pettitt, A. R. (2014). Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?. PHARMACOGENOMICS, 15(7), 897-900. doi:10.2217/pgs.14.60

DOI: 10.2217/pgs.14.60

Results of the randomised phase II NCRI ADMIRE trial of FC-R and FCM-R in previously untreated CLL: oral FCR is highly effective and safe but the addition of mitoxantrone does not improve responses (Conference Paper)

Bloor, A. J. C., Cohen, D., Pocock, C., Rawstron, A., McParland, L., Chalmers, A., . . . Hillmen, P. (2014). Results of the randomised phase II NCRI ADMIRE trial of FC-R and FCM-R in previously untreated CLL: oral FCR is highly effective and safe but the addition of mitoxantrone does not improve responses. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 165 (pp. 18). Retrieved from http://gateway.webofknowledge.com/

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia (Journal article)

Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . O'Brien, S. M. (2014). Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 370, 997-1007. doi:10.1056/NEJMoa1315226

DOI: 10.1056/NEJMoa1315226

SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage (Journal article)

Clifford, R., Louis, T., Robbe, P., Ackroyd, S., Burns, A., Timbs, A. T., . . . Schuh, A. (2014). SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. BLOOD, 123(7), 1021-1031. doi:10.1182/blood-2013-04-490847

DOI: 10.1182/blood-2013-04-490847

EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era (Journal article)

Fox, C. P., Burns, D., Parker, A. N., Peggs, K. S., Harvey, C. M., Natarajan, S., . . . Chaganti, S. (2014). EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. BONE MARROW TRANSPLANTATION, 49(2), 280-286. doi:10.1038/bmt.2013.170

DOI: 10.1038/bmt.2013.170

A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia (Journal article)

Speedy, H. E., Di Bernardo, M. C., Sava, G. P., Dyer, M. J. S., Holroyd, A., Wang, Y., . . . Houlston, R. S. (2014). A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. NATURE GENETICS, 46(1), 56-+. doi:10.1038/ng.2843

DOI: 10.1038/ng.2843

Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach (Journal article)

te Raa, G. D., Malcikova, J., Mraz, M., Trbusek, M., Le Garff-Tavernier, M., Merle-Beral, H., . . . ERIC. (2014). Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. BRITISH JOURNAL OF HAEMATOLOGY, 167(4), 565-569. doi:10.1111/bjh.13006

DOI: 10.1111/bjh.13006

Motility and trafficking in B-cell non-Hodgkin's lymphoma (Review) (Journal article)

Till, K. J., Coupland, S. E., & Pettitt, A. R. (2014). Motility and trafficking in B-cell non-Hodgkin's lymphoma (Review). INTERNATIONAL JOURNAL OF ONCOLOGY, 45(1), 5-12. doi:10.3892/ijo.2014.2395

DOI: 10.3892/ijo.2014.2395

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an OpenLabel Phase II Study (Journal article)

Hillmen, P., Gribben, J. G., Follows, G. A., Milligan, D., Sayala, H. A., Moreton, P., . . . Pocock, C. F. E. (2014). Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an OpenLabel Phase II Study. JOURNAL OF CLINICAL ONCOLOGY, 32(12), 1236-+. doi:10.1200/JCO.2013.49.6547

DOI: 10.1200/JCO.2013.49.6547

Selective IAP inhibition results in sensitization of unstimulated but not CD40-stimulated chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis. (Journal article)

Zhuang, J., Laing, N., Oates, M., Lin, K., Johnson, G., & Pettitt, A. R. (2014). Selective IAP inhibition results in sensitization of unstimulated but not CD40-stimulated chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis.. Pharmacology research & perspectives, 2(6), e00081. doi:10.1002/prp2.81

DOI: 10.1002/prp2.81

Targeting Cell Metabolism In Chronic Lymphocytic Leukaemia (CLL); A Viable Therapeutic Approach? (Journal article)

E. Clapham, C., R. Pettitt, A., & R. Slupsky, J. (n.d.). Targeting Cell Metabolism In Chronic Lymphocytic Leukaemia (CLL); A Viable Therapeutic Approach?. Journal of Hematology And Oncology Research, 1(1), 7-23. doi:10.14302/issn.2372-6601.jhor-13-346

DOI: 10.14302/issn.2372-6601.jhor-13-346

2013

Abstracts (Journal article)

Abstracts (2013). British Journal of Haematology, 161, 1-81. doi:10.1111/bjh.12263

DOI: 10.1111/bjh.12263

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia (Journal article)

Johnson, G. G., Lin, K., Cox, T. F., Oates, M., Sibson, D. R., Eccles, R., . . . Pettitt, A. R. (2013). CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. BLOOD, 122(26), 4253-4258. doi:10.1182/blood-2013-07-516666

DOI: 10.1182/blood-2013-07-516666

Chemokine Unresponsiveness of Chronic Lymphocytic Leukemia Cells Results from Impaired Endosomal Recycling of Rap1 and Is Associated with a Distinctive Type of Immunological Anergy (Journal article)

Pye, D. S., Rubio, I., Pusch, R., Lin, K., Pettitt, A. R., & Till, K. J. (2013). Chemokine Unresponsiveness of Chronic Lymphocytic Leukemia Cells Results from Impaired Endosomal Recycling of Rap1 and Is Associated with a Distinctive Type of Immunological Anergy. The Journal of Immunology, 191(3), 1496-1504. doi:10.4049/jimmunol.1203484

DOI: 10.4049/jimmunol.1203484

2012

Advances in the understanding of the mechanisms of glucocorticoid sensitivity and resistance in lymphoid malignancies (Journal article)

Zhuang, J., & Pettitt, A. R. (2012). Advances in the understanding of the mechanisms of glucocorticoid sensitivity and resistance in lymphoid malignancies. Current Topics in Steroid Research, 9, 93-109.

Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial (Journal article)

Pettitt, A. R., Jackson, R., Carruthers, S., Dodd, J., Dodd, S., Oates, M., . . . Hillmen, P. (2012). Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial. JOURNAL OF CLINICAL ONCOLOGY, 30(14), 1647-1655. doi:10.1200/JCO.2011.35.9695

DOI: 10.1200/JCO.2011.35.9695

Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak (Journal article)

Melarangi, T., Zhuang, J., Lin, K., Rockliffe, N., Bosanquet, A. G., Oates, M., . . . Pettitt, A. R. (2012). Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak. CELL DEATH & DISEASE, 3. doi:10.1038/cddis.2012.102

DOI: 10.1038/cddis.2012.102

The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes in chromosome 17p (Journal article)

Lin, K., Lane, B., Carter, A., Johnson, G. G., Onwuazor, O., Oates, M., . . . Pettitt, A. R. (2012). The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes in chromosome 17p. British Journal of Haematology.

2011

A randomised Phase II Trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia (Journal article)

Hillmen, P., Cohen, D., Cocks, K., Pettitt, A. R., Sayala, H., Rawstrom, A., . . . Pocock, C. (2011). A randomised Phase II Trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. British Journal of Haematology, 152(5), 570-578.

Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration (Journal article)

Lin, K., Adamson, J., Johnson, G. G., Carter, A., Oates, M., Wade, R., . . . Pettitt, A. R. (2012). Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration. CLINICAL CANCER RESEARCH, 18(15), 4191-4200. doi:10.1158/1078-0432.CCR-11-2936

DOI: 10.1158/1078-0432.CCR-11-2936

Incurable, Invisible and Inconclusive: Watchful Waiting for Chronic Lymphocytic Leukaemia and Implications for Doctor-Patient Communication (Journal article)

Evans, J., Ziebland, S., & Pettitt, A. R. (2011). Incurable, Invisible and Inconclusive: Watchful Waiting for Chronic Lymphocytic Leukaemia and Implications for Doctor-Patient Communication. European Journal of Cancer Care, 1365-2354.

Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p. (Journal article)

Arumainathan, A., Kalakonda, N., & Pettitt, A. R. (2011). Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.. European journal of haematology, 87(4), 372-375. doi:10.1111/j.1600-0609.2011.01667.x

DOI: 10.1111/j.1600-0609.2011.01667.x

2010

Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition (Journal article)

Zhuang, J., Hawkins, S. F., Glenn, M. A., Lin, K., Johnson, G. G., Carter, A., . . . Pettitt, A. R. (2010). Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95(1), 110-118. doi:10.3324/haematol.2009.010272

DOI: 10.3324/haematol.2009.010272

Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. (Journal article)

Crowther-Swanepoel, D., Broderick, P., Di Bernardo, M. C., Dobbins, S. E., Torres, M., Mansouri, M., . . . Houlston, R. S. (2010). Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk.. Nature genetics, 42(2), 132-136. doi:10.1038/ng.510

DOI: 10.1038/ng.510

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD and immune reconstitution (Journal article)

Chakraverty, R., Orti, G., Roughton, M., Shen, J., Fielding, A., Kottaridis, P., . . . Mackinnon, S. (2010). Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD and immune reconstitution. Blood, 116(16), 3080-3088.

Ribosome-associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia (Journal article)

Rees-Unwin, K. S., Faragher, R., Unwin, R. D., Adams, J., Brown, P. J., Buckle, A. M., . . . Burthem, J. (2010). Ribosome-associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia. British Journal of Haematology, 148(4), 534-543.

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations (Journal article)

Zenz, T., Vollmer, D., Trbusek, M., Smardova, J., Benner, A., Soussi, T., . . . Stilgenbauer, S. (2010). TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia, 24(12), 2072-2079. doi:10.1038/leu.2010.208

DOI: 10.1038/leu.2010.208

Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia (Journal article)

Allan, J. M., Sunter, N. J., Bailey, J. R., Pettitt, A. R., Harris, R. J., Pepper, C., . . . Allsup, D. J. (2010). Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. LEUKEMIA, 24(4), 877-881. doi:10.1038/leu.2009.298

DOI: 10.1038/leu.2009.298

p53 dysfunction in chronic lymphocytic leukemia (Chapter)

Pospisilova, S., & Pettitt, A. R. (2010). p53 dysfunction in chronic lymphocytic leukemia. In K. Stamatopoulos, P. Ghia, & R. Rosenquist (Eds.), New Biological Prognostic Markers in Chronic Lymphocytic Leukemia (pp. 73-95). Italy: Walter Kluyers Health Ltd.

2009

A Novel Type of p53 Pathway Dysfunction in Chronic Lymphocytic Leukemia Resulting from Two Interacting Single Nucleotide Polymorphisms within the p21 Gene (Journal article)

Johnson, G. G., Sherrington, P. D., Carter, A., Lin, K., Liloglou, T., Field, J. K., & Pettitt, A. R. (2009). A Novel Type of p53 Pathway Dysfunction in Chronic Lymphocytic Leukemia Resulting from Two Interacting Single Nucleotide Polymorphisms within the p21 Gene. CANCER RESEARCH, 69(12), 5210-5217. doi:10.1158/0008-5472.CAN-09-0627

DOI: 10.1158/0008-5472.CAN-09-0627

Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy (Journal article)

Faderl, S., Ferrajoli, A., Frankfurt, O., & Pettitt, A. (2009). Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Leukemia, 23(3), 457-466. doi:10.1038/leu.2008.322

DOI: 10.1038/leu.2008.322

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome (Journal article)

Robinson, S. P., Sureda, A., Canals, C., Russell, N., Caballero, D., Bacigalupo, A., . . . Schmitz, N. (2009). Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica, 94(2), 230-238. doi:10.3324/haematol.13441

DOI: 10.3324/haematol.13441

Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244 (Journal article)

Hoskin, P. J., Lowry, L., Horwich, A., Jack, A., Mead, B., Hancock, B. W., . . . Johnson, P. W. M. (2009). Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. Journal of Clinical Oncology, 27(32), 5390-5396. doi:10.1200/jco.2009.23.3239

DOI: 10.1200/jco.2009.23.3239

Results of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolone for high-risk (17p-) CLL (Journal article)

Pettitt, A. R., Matutes, E., Dearden, C., Oscier, D. G., Carruthers, S., Dodd, S., . . . Hillmen, P. (2009). Results of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolone for high-risk (17p-) CLL. Hematologica, 94, 351a.

2008

Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells (Journal article)

Lin, K., Rockliffe, N., Johnson, G. G., Sherrington, P. D., & Pettitt, A. R. (2008). Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene, 27(17), 2445-2455. doi:10.1038/sj.onc.1210893

DOI: 10.1038/sj.onc.1210893

A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. (Journal article)

Di Bernardo, M. C., Crowther-Swanepoel, D., Broderick, P., Webb, E., Sellick, G., Wild, R., . . . Houlston, R. S. (2008). A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.. Nature genetics, 40(10), 1204-1210. doi:10.1038/ng.219

DOI: 10.1038/ng.219

DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia (Journal article)

Willmore, E., Elliott, S. L., Mainou-Fowler, T., Summerfield, G. R., Jackson, G. H., O'Neill, F., . . . Durkacz, B. W. (2008). DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. CLINICAL CANCER RESEARCH, 14(12), 3984-3992. doi:10.1158/1078-0432.CCR-07-5158

DOI: 10.1158/1078-0432.CCR-07-5158

Glucocorticoid-based combination therapy for chronic lymphotic leukemia: new tricks for an old dog (Journal article)

Pettitt, A. R. (2008). Glucocorticoid-based combination therapy for chronic lymphotic leukemia: new tricks for an old dog. Leukemia & Lymphoma, 49(10), 1843-1845. doi:10.1080/10428190802455883

DOI: 10.1080/10428190802455883

2007

The development of sarcoidosis with the use of alemtuzumab ? clues to T-cell immune reconstitution (Journal article)

Thachil, J., Jadhav, V., Gautam, M., Mckew, S., Arumainathan, A., Collins, D., . . . Pettitt, A. (2007). The development of sarcoidosis with the use of alemtuzumab ? clues to T-cell immune reconstitution. British Journal of Haematology, 138(4), 559-560. doi:10.1111/j.1365-2141.2007.06687.x

DOI: 10.1111/j.1365-2141.2007.06687.x

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial (Journal article)

Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M. J. S., Bezares, R. F., . . . Hillmen, P. (2007). Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. The Lancet, 370(9583), 230-239. doi:10.1016/s0140-6736(07)61125-8

DOI: 10.1016/s0140-6736(07)61125-8

The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia (Journal article)

Kay, N. E., O'Brien, S. M., Pettitt, A. R., & Stilgenbauer, S. (2007). The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. LEUKEMIA, 21(9), 1885-1891. doi:10.1038/sj.leu.2404802

DOI: 10.1038/sj.leu.2404802

2006

Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects (Journal article)

Pettitt, A. R., Matutes, E., & Oscier, D. (2006). Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia, 20(8), 1441-1445. doi:10.1038/sj.leu.2404265

DOI: 10.1038/sj.leu.2404265

Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia (Journal article)

Carter, A., Lin, K., Sherrington, P. D., Atherton, M., Pearson, K., Douglas, A., . . . Pettitt, A. R. (2006). Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia. Leukemia, 20(4), 737-740. doi:10.1038/sj.leu.2404120

DOI: 10.1038/sj.leu.2404120

2005

Analysis of VH gene sequences using two web-based immunogenetics resources gives different results, but the affinity maturation status of chronic lymphocytic leukaemia clones as assessed from either of the resulting data sets has no prognostic significance (Journal article)

Lane, B. S., Mensah, A. A., Lin, K., Pettitt, A. R., & Sherrington, P. D. (2005). Analysis of VH gene sequences using two web-based immunogenetics resources gives different results, but the affinity maturation status of chronic lymphocytic leukaemia clones as assessed from either of the resulting data sets has no prognostic significance. Leukemia, 19(5), 741-749. doi:10.1038/sj.leu.2403720

DOI: 10.1038/sj.leu.2403720

Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia (Journal article)

Romanov, V. V., James, C. H., Sherrington, P. D., & Pettitt, A. R. (2005). Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia. Oncogene, 24(45), 6855-6860. doi:10.1038/sj.onc.1208895

DOI: 10.1038/sj.onc.1208895

2004

Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia (Journal article)

Carter, A., Lin, K., Sherrington, P. D., & Pettitt, A. R. (2004). Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. British Journal of Haematology, 127(4), 425-428. doi:10.1111/j.1365-2141.2004.05223.x

DOI: 10.1111/j.1365-2141.2004.05223.x

Down-regulation of BCL-2 and its prevention by interleukin-4 in cultured chronic lymphocytic leukaemia cells is a methodological artefact caused by failure of protein detection/extraction following the onset of cell death (Journal article)

Kamiguti, A. S., Moran, E. C., & Pettitt, A. R. (2004). Down-regulation of BCL-2 and its prevention by interleukin-4 in cultured chronic lymphocytic leukaemia cells is a methodological artefact caused by failure of protein detection/extraction following the onset of cell death. British Journal of Haematology, 127(2), 236-238. doi:10.1111/j.1365-2141.2004.05184.x

DOI: 10.1111/j.1365-2141.2004.05184.x

Natural history of CLL: Current thinking (Chapter)

Pettitt, A. R., Sherrington, P., Allsup, D. J., Matrai, Z., Cawley, J. C., & Zuzel, M. (2004). Natural history of CLL: Current thinking. In A. Miles (Ed.), UK Key Advances in Clinical Practice Series. Key Advances in the Effective Management of Chronic Lymphocytic Leukaemia (pp. not known at present). not known at present: not known at present.

The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes (Journal article)

Jones, G. G., Reaper, P. M., Pettitt, A. R., & Sherrington, P. D. (2004). The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes. Oncogene, 23(10), 1911-1921. doi:10.1038/sj.onc.1207318

DOI: 10.1038/sj.onc.1207318

2003

Correlation Between Cell Size and CD38 Expression in Chronic Lymphocytic Leukaemia (Journal article)

Manocha, S., Matrai, Z., Osthoff, M., Carter, A., & Pettitt, A. R. (2003). Correlation Between Cell Size and CD38 Expression in Chronic Lymphocytic Leukaemia. Leukemia & Lymphoma, 44(5), 797-800. doi:10.1080/1042819031000068034

DOI: 10.1080/1042819031000068034

High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment. (Journal article)

Lin, K., Manocha, S., Harris, R. J., Matrai, Z., Sherrington, P. D., & Pettitt, A. R. (2003). High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment.. Blood, 102(3), 1145-1146. doi:10.1182/blood-2003-04-1289

DOI: 10.1182/blood-2003-04-1289

Mechanism of action of purine analogues in chronic lymphocytic leukaemia (Journal article)

Pettitt, A. R. (2003). Mechanism of action of purine analogues in chronic lymphocytic leukaemia. British Journal of Haematology, 121(5), 692-702. doi:10.1046/j.1365-2141.2003.04336.x

DOI: 10.1046/j.1365-2141.2003.04336.x

2002

Cytoprotective antioxidant activity of serum albumin and autocrine catalase in (Journal article)

Moran, E. C., Kamiguti, A. S., Cawley, J. C., & Pettitt, A. R. (2002). Cytoprotective antioxidant activity of serum albumin and autocrine catalase in. Br J Haematol., 116(2), 316-328.

Relationship between p53 dysfunction, CD38 expression, andIgVH mutation in chronic lymphocytic leukemia (Journal article)

Lin, K., Sherrington, P. D., Dennis, M., Matrai, Z., Cawley, J. C., & Pettitt, A. R. (2002). Relationship between p53 dysfunction, CD38 expression, andIgVH mutation in chronic lymphocytic leukemia. Blood, 100(4), 1404-1409. doi:10.1182/blood-2001-11-0066

DOI: 10.1182/blood-2001-11-0066

Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion (Journal article)

Baker, P. K., Pettitt, A. R., Slupsky, J. R., Chen, H. J., Glenn, M. A., Zuzel, M., & Cawley, J. C. (2002). Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion. Blood, 100(2), 647-653.

2001

CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. (Journal article)

Matrai, Z., Lin, K., Dennis, M., Sherrington, P., Zuzel, M., Pettitt, A. R., & Cawley, J. C. (2001). CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia.. Blood, 97(6), 1902-1903.

Homotypic interactions protect chronic lymphocytic leukaemia cells from spontaneous death in vitro (Journal article)

Pettitt, A. R., Moran, E. C., & Cawley, J. C. (2001). Homotypic interactions protect chronic lymphocytic leukaemia cells from spontaneous death in vitro. Leukemia Research, 25(11), 1003-1012. doi:10.1016/s0145-2126(01)00067-4

DOI: 10.1016/s0145-2126(01)00067-4

p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative toTP53 mutation (Journal article)

Pettitt, A. R., Sherrington, P. D., Stewart, G., Cawley, J. C., Taylor, A. M. R., & Stankovic, T. (2001). p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative toTP53 mutation. Blood, 98(3), 814-822. doi:10.1182/blood.v98.3.814

DOI: 10.1182/blood.v98.3.814

2000

Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic lymphocytic leukaemia (Journal article)

Pettitt, A. R., & Cawley, J. C. (2000). Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic lymphocytic leukaemia. British Journal of Haematology, 109(4), 800-804. doi:10.1046/j.1365-2141.2000.02068.x

DOI: 10.1046/j.1365-2141.2000.02068.x

Granulocyte-macrophage colony-stimulating factor as an autocrine survival factor for mature normal and malignant B lymphocytes. (Journal article)

Harris, R. J., Pettitt, A. R., Schmutz, C., Sherrington, P. D., Zuzel, M., Cawley, J. C., & Griffiths, S. D. (2000). Granulocyte-macrophage colony-stimulating factor as an autocrine survival factor for mature normal and malignant B lymphocytes.. Journal of immunology (Baltimore, Md. : 1950), 164(7), 3887-3893. doi:10.4049/jimmunol.164.7.3887

DOI: 10.4049/jimmunol.164.7.3887

Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues. (Journal article)

Pettitt, A. R., Sherrington, P. D., & Cawley, J. C. (2000). Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.. Cancer Res., 60(15), 4187-4193.

1999

Hairy-cell leukaemia: biology and management. (Journal article)

Pettitt, A. R., Zuzel, M., & Cawley, J. C. (1999). Hairy-cell leukaemia: biology and management.. Br J Haematol., 106(1), 2-8.

Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms (Journal article)

Pettitt, A. R., Clarke, A. R., Cawley, J. C., & Griffiths, S. D. (1999). Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms. British Journal of Haematology, 105(4), 986-988. doi:10.1046/j.1365-2141.1999.01448.x

DOI: 10.1046/j.1365-2141.1999.01448.x

The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia (Journal article)

Pettitt., Sherrington., & Cawley. (1999). The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. British Journal of Haematology, 106(4), 1049-1051. doi:10.1046/j.1365-2141.1999.01649.x

DOI: 10.1046/j.1365-2141.1999.01649.x

1995

An assessment of the Coulter VCS automated differential counter scatterplots in the recognition of specific acute leukaemia variants. (Journal article)

Pettitt, A. R., Grace, P., & Chu, P. (1995). An assessment of the Coulter VCS automated differential counter scatterplots in the recognition of specific acute leukaemia variants.. Clin Lab Haematol., 17(2), 125-129.

1994

Thrombotic microangiopathy following bone marrow transplantation. (Journal article)

Pettitt, A. R., & Clark, R. E. (1994). Thrombotic microangiopathy following bone marrow transplantation.. Bone Marrow Transplant., 14(4), 495-504.

Vogt-Koyanagi-Harada syndrome complicating allogeneic bone marrow transplantation. (Journal article)

Pettitt, A. R., Neoh, C., Wong, S. H., & Clark, R. E. (1994). Vogt-Koyanagi-Harada syndrome complicating allogeneic bone marrow transplantation.. Bone Marrow Transplant., 13(2), 225-227.